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SUMMARY
Highly efficient CD8+ T cells are associated with natural HIV control, but it has remained unclear how these
cells are generated and maintained. We have used a macaque model of spontaneous SIVmac251 control
to monitor the development of efficient CD8+ T cell responses. Our results show that SIV-specific CD8+
T cells emerge during primary infection in all animals. The ability of CD8+ T cells to suppress SIV is suboptimal
in the acute phase but increases progressively in controller macaques before the establishment of sustained
low-level viremia. Controller macaques develop optimal memory-like SIV-specific CD8+ T cells early after
infection. In contrast, a persistently skewed differentiation phenotype characterizes memory SIV-specific
CD8+ T cells in non-controller macaques. Accordingly, the phenotype of SIV-specific CD8+ T cells defined
early after infection appears to favor the development of protective immunity in controllers, whereas SIV-spe-
cific CD8+ T cells in non-controllers fail to gain antiviral potency, feasibly as a consequence of early defects
imprinted in the memory pool.
INTRODUCTION
The ability of CD8+ T cells to control viral replication has been
extensively documented in the setting of HIV/simian immunode-
ficiency virus (SIV) infection (McBrien et al., 2018; Walker and
McMichael, 2012). Primary infection is characterized by massive
viremia, which subsides following the expansion of HIV/SIV-spe-
cific CD8+ T cells (Borrow et al., 1994; Koup et al., 1994).
However, the virus is not eradicated, leading to the emergence
of immune escape variants (Allen et al., 2000; Borrow et al.,
1997; O’Connor et al., 2002; Price et al., 1997) and ongoing an-
tigen exposure, which drives CD8+ T cell exhaustion during the
chronic phase of infection (Day et al., 2006; Petrovas et al.,
2006, 2007; Trautmann et al., 2006). These observations suggest
that naturally generated HIV/SIV-specific CD8+ T cells are
frequently suboptimal in terms of antiviral efficacy, potentially re-
flecting limited cross-reactivity and/or intrinsic defects in the
arsenal of effector functions required to eliminate infected
CD4+ T cells (Du et al., 2016; Le´curoux et al., 2013). The latter
possibility is especially intriguing in light of ex vivo experiments
showing that effective suppression of viral replication is a partic-
ular feature of CD8+ T cells isolated from HIV controllers (HICs)
(Angin et al., 2016; Sa´ez-Cirio´n et al., 2007, 2009; Tansiri et al.,
2015).
HICs are a rare group of individuals who control viremia to low
levels without antiretroviral therapy (Sa´ez-Cirio´n and Pancino,
2013). Understanding the mechanisms associated with such
spontaneous control of HIV infection seems crucial for the devel-
opment of new strategies designed to achieve remission. Effi-
cient CD8+ T cell responses are almost universally present in
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HICs (Betts et al., 2006; Chowdhury et al., 2015; Hersperger
et al., 2010, 2011a; Migueles et al., 2002, 2008; Sa´ez-Cirio´n
et al., 2007, 2009; Zimmerli et al., 2005). These individuals also
frequently express the protective human leukocyte antigen
(HLA) class I allotypes HLA-B*27 or HLA-B*57, supporting a
key role for CD8+ T cells in the natural control of HIV (Le´curoux
et al., 2014; Migueles et al., 2000; Pereyra et al., 2008). However,
the presence of these allotypes is not sufficient to confer protec-
tion, and potent CD8+ T cell responses with the ability to sup-
press HIV replication directly ex vivo also occur in HICs express-
ing non-protective allotypes (Le´curoux et al., 2014). In addition,
the qualitative properties of CD8+ T cells from HICs have only
been characterized extensively during chronic infection, when
viremia was already under control, often several years after the
acquisition of HIV. It has therefore remained unclear how these
high-quality CD8+ T cell responses develop from the early stages
of infection and evolve over time.
Cynomolgus macaques (CyMs, Macaca fascicularis) infected
with SIVmac251 closely recapitulate the dynamics and key fea-
tures of HIV infection, including similar levels of viral replication in
the acute and chronic phases of infection, memory CD4+ T cell
depletion, rapid seeding of the viral reservoir, and eventual pro-
gression to AIDS (Antony and MacDonald, 2015; Feichtinger
et al., 1990; Karlsson et al., 2007;Mannioui et al., 2009; Putkonen
et al., 1989). Moreover, some individuals control infection natu-
rally, as in humans. CyMs from Mauritius offer the additional
advantage of limited major histocompatibility complex (MHC) di-
versity, making them particularly attractive for the study of CD8+
T cell responses. Natural control of SIV in Mauritian CyMs is
favored by the MHC haplotype M6 (Aarnink et al., 2011; Mee
et al., 2009). Inoculation with low-dose SIV via the intrarectal
(i.r.) route is also associated with natural control, irrespective of
MHC haplotype (Bruel et al., 2015). We took advantage of these
validated models to study the dynamics of SIV-specific CD8+
T cell responses in blood and tissues from the onset of infection
in controllers and viremic CyMs (VIRs). Using this approach, we
identified an optimal maturation pathway in SICs that enabled
SIV-specific CD8+ T cells to acquire potent antiviral functions,
which contributed to control of the infection.
RESULTS
SIVControllers Are Characterized by Partial Restoration
of CD4+ T Cell Counts and Progressive Decline in the
Frequency of SIV-Infected Cells in Blood
We monitored prospectively the outcome of infection in 12 SIV
controllers (SICs) and 4 VIRs inoculated i.r. with SIVmac251.
These animals carried or not the protective M6 haplotype and
were inoculated with an animal infectious dose 50 (AID50) of
5AID50 or 50AID50 of SIVmac251 (Table S1). SICs decreased
plasma viral load (VL) to levels below 400 SIV-RNA copies/mL
at least twice over a follow-up period of 18 months, whereas
VIRs consistently maintained VL to levels above 400 SIV-RNA
copies/mL. The threshold of 400 RNA copies/mL was chosen
in coherence with our studies in human cohorts of natural HIV
control (Angin et al., 2016; Noel et al., 2016; Sa´ez-Cirio´n et al.,
2007, 2009, 2013). Ten SICs achieved control of viremia within
3 months. The other two SICs (BL669 and BO413) achieved VL
below 400 SIV-RNA copies/mL for the first time 14 months after
inoculation. One VIR (AV979) developed a tonsillar lymphoma, an
AIDS-related event reported at high frequency in this species
upon SIV infection (Feichtinger et al., 1990).
Some differences in peak viremia were observed between
SICs and VIRs (Figure 1A; Table S2). These differences became
more pronounced over time (Figure 1A), because plasma viremia
was suppressed more rapidly in SICs versus VIRs (Table S2).
Levels of cell-associated SIV-DNA in blood from SICs and
VIRs were comparable before peak viremia, but differences
became apparent as plasma VLs declined and were maintained
throughout chronic infection (Figure 1C; Table S2). Likewise,
CD4+ T cells obtained during early infection from SICs and
VIRs produced similar levels of p27 upon stimulation ex vivo
with concanavalin A (ConA) and interleukin (IL) 2 (Figure S1A).
However, although p27 production remained relatively stable in
VIRs, these levels strongly dropped overtime in SICs. We found
a significant correlation between the levels of p27 production by
CD4+ T cells and the levels of SIV-DNA (r = 0.775; p = 0.0002,
6 months post-infection [p.i.]). Therefore, our results show that
SICs progressively reduced not only the frequency of total in-
fected cells but also the translation-competent reservoir. In addi-
tion, CD4+ T cell counts declined markedly in blood from both
SICs and VIRs during primary infection (Figure 1B; Table S2).
Subsequently, a degree of recovery was observed in SICs,
whereas further gradual declinewas observed in VIRs (Figure 1B;
Table S2).
These results showed the distinctive dynamics of SIV infection
in SICs and VIRs, characterized by modest differences during
the early weeks following inoculation that were progressively
exacerbated during transition to chronic infection. The differ-
ences between SICs and VIRs during the chronic phase of SIV
infection were consistent with observations in human cohorts
of HICs.
SIV Control Is Associated with Early Preservation of
Lymph Nodes
To characterize the extent of SIV control in greater depth, we
monitored CD4+ T cells and total SIV-DNA longitudinally in pe-
ripheral lymph nodes (PLNs) and rectal biopsies (RBs). At the
end of the study, we conducted similar evaluations in bone
marrow, spleen, mesenteric lymph nodes (MLNs), and colonic
mucosa, comparing SICs versus VIRs. The frequency of CD4+
T cells similarly declined in RBs from SICs and VIRs during the
acute stage of primary infection. Although the frequency of
CD4+ T cells was later partially restored in SICs, it continued to
decline in VIRs (Figure 1D). These results matched the observa-
tions in blood samples (Figure 1B). In contrast, the frequency of
CD3+ lymphocytes relative to baseline in RBs and PLNs. (F) Percentage of frequency of CD4+ T cells among CD3+ lymphocytes in bone marrow, spleen, PLNs,
MLNs, and colon mucosa at euthanasia. Kinetics of SIV-DNA levels in blood (C), RBs (G), and PLNs (H).
(I) Levels of SIV-DNA in bone marrow, spleen, PLNs, MLNs, and colon at euthanasia. Results are expressed as copies of SIV-DNA per million CD4+ T cells.
Median and interquartile range are shown (n = 12 SICs; n = 4 VIRs). *p < 0.05, **p < 0.01; Mann-Whitney U test.
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CD4+ T cells was maintained close to baseline in PLNs from
SICs, even during primary infection (day 14 p.i.) but steadily
declined over time in VIRs (Figure 1E). At the time of euthanasia,
CD4+ T cell frequencies were substantially higher in blood (Fig-
ure 1B), bonemarrow, spleen, PLNs, MLNs, and colonic mucosa
(Figure 1F) from SICs versus VIRs.
Cell-associated SIV-DNA levels closely mirrored the dynamics
of CD4+ T cells. Similarly high levels of cell-associated SIV-DNA
were observed in RBs from SICs and VIRs during primary infec-
tion, but lower levels were observed in RBs from SICs versus
VIRs during chronic infection (Figure 1G). SIV-DNA levels were
already approximately 1 log lower in PLNs versus RBs from
SICs during primary infection, and accordingly, lower levels
were observed in PLNs from SICs versus VIRs since day 14
p.i. (Figure 1H). This finding suggests that early viral replication
may be contained more efficiently in lymphoid nodes in SICs
compared with other explored anatomical compartments. SIV-
DNA was also detected in alveolar macrophages from all CyMs
throughout the course of infection, again at lower levels in SICs
versus VIRs during chronic infection (Figure S1B). In addition,
SIV-DNA levels tended to decline progressively over time in
SICs in all tissues analyzed, whereas SIV-DNA levels remained
stable after primary infection in VIRs (Figures 1C, 1G, and 1H).
At the time of euthanasia, SIV-DNA levels were substantially
lower in blood (Figure 1C), bone marrow, PLNs, MLNs, and gut
mucosa (Figure 1I; Figure S1C) from SICs versus VIRs.
Collectively, these data indicate that progressive systemic
control of viral replication is achieved in SICs with CD4+ T cell
preservation and lower pan-anatomical reservoirs of SIV-DNA.
Our results also underline the early preservation of PLNs in these
animals.
The Dynamics of CD8+ T Cell Expansion and Activation
Do Not Predict Control of SIV
To understand the mechanisms that contribute to immune con-
trol of SIV, we first monitored the proliferation and activation dy-
namics of total CD8+ T cells in blood and lymphoid tissues from
SICs and VIRs. Recent studies in hyperacute HIV-infected indi-
viduals indicate that the changes observed in total CD8+ T cell
activation during acute infection may be largely related to
changes in the HIV-specific CD8+ T cell pool (Ndhlovu et al.,
2015; Takata et al., 2017). The frequencies of CD8+ T cells ex-
pressing Ki-67 in blood increased to maximum levels during pri-
mary infection (measured peak at day 15 p.i.), coinciding with the
measured peak of viremia, and then declined steadily to baseline
levels during chronic infection (Figure 2A). Similar dynamicswere
observed in PLNs (Figure 2B) and gut mucosa (Figure 2C). In
general, there were no significant differences between SICs
and VIRs with respect to the dynamics of Ki-67 expression within
the CD8+ T cell pool, although lower frequencies of CD8+ T cells
expressing Ki-67 were observed during chronic infection in PLNs
from SICs versus VIRs (Figure 2B).
The frequencies of CD8+ T cells expressing the activation
markers CD38 and HLA-DR in blood, PLNs, and gut mucosa
increased similarly during primary infection (measured peak at
day 28 p.i.), following the dynamics of Ki-67 expression in the
same compartments (Figures 2D–2F). Again, there were no signif-
icant differences between SICs and VIRs with respect to the early
dynamics of total CD8+ T cell activation, but lower frequencies of
CD8+ T cells expressingCD38 andHLA-DRwere observed during
chronic infection in PLNs from SICs versus VIRs (Figure 2E).
Overall, our findings indicate that although lower activation
and proliferation are observed in of CD8+ T cells from SICs
than from VIRs in the chronic stage of infection, the early prolif-
eration and activation dynamics of the total pool of CD8+
T cells do not distinguish subsequent progression rates.
SIV-Specific CD8+ T Cell Frequencies Do Not Predict
Control of SIV
We analyzed CD8+ T cell responses to a pool of optimal SIV-
mac251 peptides, which included peptides from different SIV
proteins recognized by the most frequent MHC haplotypes in
CyMs (M1, M2, and M3) and by the MHC haplotype M6 (Table
S3). All animals carried at least one haplotype matching some
peptide, and overall there was no difference in the number of
tested peptides theoretically recognized in SICs and VIRs (p =
0.35). SIV-specific CD8+ T cells producing tumor necrosis factor
alpha (TNF-a, the cytokine showing the lowest background in the
absence of peptide or in presence of peptide during the baseline
and hence used as reference) emerged in all CyMs during pri-
mary infection, coinciding with the peak of viremia, and no signif-
icant differences were observed between SICs and VIRs with
respect to the frequencies of these cells in any anatomical
compartment at any stage of infection (Figure 3A). Similarly, no
consistent differences were observed between SICs and VIRs
with respect to the frequencies of SIV-specific CD8+ T cells
that produced other cytokines, including interferon gamma
(IFNg) (Figure S2A) and IL-2 (Figure S2B), or mobilized CD107a
(Figure S2C). The overall SIV-specific CD8+ T cell response,
determined in each CyM as the frequency of cells displaying at
least one function (TNF-a, IFNg, IL-2, or CD107a), was also
equivalent between SICs and VIRs across anatomical compart-
ments throughout infection (Figure S2D). In addition, no clear dif-
ferences between SICs and VIRs were observed with respect to
the frequencies of SIV-specific CD8+ T cells displaying at least
three functions simultaneously in blood or PLNs during acute
infection, but higher frequencies of polyfunctional SIV-specific
CD8+ T cells were present during chronic infection in lymphoid
tissues from SICs versus VIRs (Figure 3B; Figure S2E). Differ-
ences also were not observed in themagnitude and polyfunction
of SIV-specific CD8+ T cells from SICs and VIRs when a pool of
overlapping peptides spanning SIV Gag was used instead of the
optimal peptide pool to stimulate the cells (Figure S3).
These data suggest that natural control of SIV is not associ-
ated with acutely generated, functionally superior SIV-specific
CD8+ T cell responses defined on the basis of cytokine produc-
tion and degranulation.
Progressive Acquisition of CD8+ T Cell-Mediated SIV-
Suppressive Activity Is Associated with Control of SIV
CD8+ T cells from HICs typically suppress ex vivo infection of
autologous CD4+ T cells (Angin et al., 2016; Buckheit et al.,
2012; Julg et al., 2010; Sa´ez-Cirio´n et al., 2007, 2009; Tansiri
et al., 2015). We therefore investigated this property as a poten-
tial discriminant between SICs and VIRs. The capacity of CD8+
T cells in blood and PLNs to suppress infection of autologous
4 Cell Reports 32, 108174, September 22, 2020
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CD4+ T cells was relatively weak in all CyMs during acute infec-
tion (Figure 4A), but this activity correlated negatively with VL on
day 15 p.i. (Figure 4B, upper panel), suggesting its contribution
to control viremia since early time points. Interestingly, the
CD8+ T cell-mediated SIV-suppressive activity increased sub-
stantially over time in SICs (Figure 4A; Figure S4A), either in blood
or in tissues. No such acquisition of SIV-suppressive activity was
observed in VIRs (Figure 4A; Figure S4A). Moreover, CD8+ T cell-
mediated SIV-suppressive activity on day 70 p.i. correlated
negatively (or tended to correlate) with subsequent determina-
tions of plasma VL (Figure S4B), and there was a negative corre-
lation between the CD8+ T cell-mediated SIV-suppressive activ-
ity at euthanasia and the VL at this time (Figure 4C, upper
panels). In contrast, we never found negative correlations be-
tween VL (at any given time) and the suppressive capacity of
CD8+ T cells measured at subsequent time points. No significant
correlations were identified at any time point between SIV-spe-
cific CD8+ T cell frequencies, categorized according to TNF-a
production in response to SIV peptides, and measurements of
plasma VL (Figures 4B and 4C; Figure S4B, bottom panels).
Moreover, CD8+ T cell-mediated SIV-suppressive activity across
the follow-up period, quantified as the area under the curve,
tended to correlate negatively with plasma VL (rs =!0.47, p =
0.07), whereas no such association was identified for the fre-
quency of SIV-specific CD8+ T cells (rs = !0.01, p = 0.97) (Fig-
ure 4D). All these results indicate that changes in the suppressive
capacity of CD8+ T cell, but not in the frequency of SIV-specific
CD8+ T cells, were associated with SIV control. We have previ-
ously shown that strong HIV-suppressive capacity of CD8+
T cells from HIV-1 controllers was linked to their ability to rapidly
eliminate ex vivo autologous infected cells through cytotoxic
mechanisms (Sa´ez-Cirio´n et al., 2007). Although we could not
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Figure 2. The Dynamics of CD8+ T Cell Expansion and Activation Do Not Predict Control of SIV
(A–C) Evolution of Ki-67+ CD8+ T cells in blood (A), PLNs (B), and rectal mucosa (C) in SICs (gray) and viremics (red).
(D–F) Evolution of CD38+ HLA-DR+ CD8+ T cells in blood (D), PLNs (E), and RB (F).
Median and interquartile range are shown. Vertical dashed lines indicate peak VLs. *p < 0.05, **p < 0.01; Mann-Whitney U test.
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repeat here all analyses we did in our studies in cohorts of HICs,
we could confirm that the capacity of CD8+ T cells to suppress
SIV infection ex vivo required contact with infected CD4+
T cells, and it was lost when CD8+ and CD4+ T cells were sepa-
rated by transwell membranes (Figure S5A).
Our results exposed a disconnection between the develop-
ment of SIV-specific CD8+ T cells responding to SIV peptides
and the ability of these cells to suppress SIV infection, as
measured in our viral inhibition assay ex vivo (Figure 4E; Fig-
ure S4A). SIV-specific CD8+ T cell frequencies increased sharply
as the initial viremia began to fall and remained high for the dura-
tion of the study in CyMs, irrespective of their level of viremia.
However, the substantial decline in viremia to levels below 400
copies/mL in SICs coincided with the rise of SIV-suppressive ac-
tivity. The increase of CD8+ T cell-mediated SIV-suppressive ac-
tivity was delayed in the late controllers BL669 and BO413, but
nonetheless preceded optimal control of VL in these CyMs (Fig-
ure S4A). A strong capacity of CD8+ T cells to suppress SIV was
observed at day 36 in the lymph nodes (LNs) from two animals
(BA209 and BC657) that did not show such capacity in the blood
(Figure 4A). Only one animal (29925) did not develop detectable
SIV-suppressive activity during our follow-up. This animal had
the weakest peak of viremia (1 log lower than any other) and
achieved the fastest control (Figure S4A). Whether rapid or local
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(gray) and VIRs (red). Results are shown as the percentage of frequency among CD8+ T cells. Median and interquartile range are shown (n = 12 SICs; n = 4 VIRs).
(B) Functional profiles of SIV-specific CD8+ T cells in blood and PLNs over the course of infection and in bonemarrow, spleen, andMLNs at euthanasia. Doughnut
charts show the median percentage of frequency of SIV-specific CD8+ T cells expressing IFNg, TNF-a, IL-2, and/or CD107a (n = 12 SICs; n = 4 VIRs). Colors
indicate number of simultaneous functions (blue, 1; green, 2; yellow, 3; red, 4).
*p < 0.05; Mann-Whitney U test.
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Figure 4. Progressive Acquisition of CD8+ T Cell-Mediated SIV-Suppressive Activity Is Associated with Control of SIV
(A) CD8+ T cell-mediated SIV-suppressive activity in blood and PLNs over the course of infection and in bone marrow, spleen, and MLNs at euthanasia in SICs
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(legend continued on next page)
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development of the CD8+ T cell suppressive capacity may have
occurred or other mechanisms were associated with control of
viremia in this animal remains unknown. At the time of eutha-
nasia, superior CD8+ T cell-mediated SIV-suppressive activity
was detected in most SICs across all anatomical compartments,
with the exception of bone marrow (Figure 4A), which nonethe-
less harbored SIV-specific CD8+ T cells at frequencies compara-
ble to those of other tissues (Figure 3A). Thus, although abun-
dant, SIV-specific CD8+ T cells induced during primary SIV
infection had limited SIV-suppressive capacity when compared
with cells found at later time points in SICs.
One limitation of our study was the reduced number of
viremic animals we could compare in parallel to SICs. To
confirm that the capacity of CD8+ T cells to suppress ex vivo
SIV infection did not increase in VIRs, we analyzed this activity
in an additional group of 14 non-M6 CyMs infected intrave-
nously (i.v.) with 1,000AID50 of SIVmac251 and characterized
by high-setpoint viremia (ANRS primate-viro-immunologic sus-
tained control after treatment interruption [pVISCONTI] study).
In these animals, the CD8+ T cell-mediated SIV-suppressive
activity remained modest throughout the follow-up (Figure S6A).
The combined analysis of the CD8+ T cells from all VIRs (n = 4
50AID50 + n = 14 1,000AID50) exposed early significant differ-
ences in the CD8+ T cell-mediated SIV-suppressive activity
when compared with the SICs (p = 0.052 at day 36 p.i. and
p < 0.05 at days 70 and 169 p.i.; Figure S6B) and significantly
higher capacity to suppress SIV infection of CD8+ T cells from
SICs than of cells from VIRs in all tissues analyzed at the end of
the study (Figure S6B). Moreover, early initiation (day 28 p.i.) of
antiretroviral treatment in another group of CyMs inoculated
with 1,000AID50 of SIVmac251 sharply decreased VL and
CD8+ T cell activation levels (Figure S6C) but did not change
the capacity of CD8+ T cells from these animals to suppress
infection ex vivo, which remained extremely weak (Figure S6C).
These results, which are in agreement with our previous obser-
vations in early-treated HIV-infected individuals (Le´curoux
et al., 2013), show that low SIV-suppressive capacity during
acute infection was a consequence neither of strong activation
of these cells in vivo nor of high antigen burden.
Finally, one possible explanation for theweak SIV-suppressive
capacity of CD8+ T cells from VIRs was that they had limited ca-
pacity to recognize the SIVmac251 we used in our viral inhibition
assay because of potential adaptation of the CD8+ T cell
response to evolving viruses in these CyMs. However, CD8+
T cells from VIRs were not able to eliminate the CD4+ T cells
that produced autologous SIV upon activation in vitro. In
contrast, although CD8+ T cells from SICs were not able to sup-
press autologous virus during early infection, they acquired this
capacity progressively at the same rate we found in our classical
protocol (Figure S5B). These results confirmed that CD8+ T cells
fromSICs and VIRs had functional differences that were unlinked
to the evolution of the infecting virus.
Collectively, our results show that the capacity of SIV-spe-
cific CD8+ T cells to suppress infection ex vivo was a genuine
quality that progressively amplified in SICs. Our results further
uncover a temporal link between acquisition by CD8+ T cells
of potent capacity to suppress infection and sustained control
of SIV.
Acquisition of CD8+ T Cell-Mediated SIV-Suppressive
Activity in SICs Occurs Independent of MHC Haplotype
Our primary intention in this study was to explore the mecha-
nisms underlying natural control of SIV infection, independent
of MHC background or infectious dose. However, as expected
(Bruel et al., 2015), inoculation with low-dose virus and carriage
of the protective M6 haplotype independently favored sponta-
neous control of viremia below 400 copies/mL in CyMs in our
study (Figure S7A; Table S4). We therefore evaluated whether
these parameters influenced the dynamics of control and the
development of the CD8+ T cell response upon infection. We
found that CD4+ T cells and the levels of cell-associated SIV-
DNA similarly evolved in the blood and PLNs from M6 and
non-M6 controllers (Figure S7B). There was a tendency for M6
controllers versus non-M6 controllers toward better recovery
of CD4+ T cells in blood at the end of the study (p = 0.07). Simi-
larly, we did not find important differences betweenM6 and non-
M6 controllers in their development of SIV-specific CD8+ T cell
responses (Figure S7C). M6 and non-M6 controllers developed
similar frequencies of SIV-responding cells during acute infec-
tion that were maintained during follow-up. The capacity of
CD8+ T cells to suppress ex vivo SIV infection of CD4+ T cells
progressively increased in both M6 and non-M6 SICs. The only
difference that we could appreciate was a faster acquisition
(day 36 p.i.) of CD8+ T cell-mediated SIV-suppressive activity
in the PLNs from M6 SICs versus non-M6 SICs (Figure S7C).
Intriguingly, non-M6 SICs had higher frequencies of SIV re-
sponding CD8+ T cells in this tissue at the same time point. Over-
all, these results show that although the M6 background gave a
selective advantage to CyMs to control infection in conditions of
higher viral inoculum, this MHC haplotypewas not indispensable
for the acquisition of SIV-suppressive capacity by CD8+ T cells,
which occurred in both M6 and non-M6 SICs. The results are in
agreement with the observations in HICs. Although cohorts of
HICs are enriched in individuals carrying protective HLA class I
alleles (mainly HLA-B*57 andHLA-B*27), manyHICs do not carry
protective HLA class I alleles but have CD8+ T cells with strong
(B) Spearman correlations between CD8+ T cell-mediated SIV-suppressive activity (upper panel) or TNF-a production by SIV-specific CD8+ T cells (bottom panel)
and plasma VL on day 15 p.i.
(C) Spearman correlations between CD8+ T cell-mediated SIV-suppressive activity (upper panel) or TNF-a production by SIV-specific CD8+ T cells (bottom panel)
and plasma VL at euthanasia.
(D) Spearman correlations between area under the curve (AUC) for plasma VL and AUC for CD8+ T cell-mediated SIV-suppressive activity (orange) and between
AUC for plasma VL and AUC for TNF-a production by SIV-specific CD8+ T cells (blue). AUC for plasma VL, TNF-a production, and CD8+ T cell antiviral activities
were calculated using the sequential values obtained throughout the duration of our study in the blood of the infected animals (Figure S7).
(E) Side-by-side comparison of the longitudinal kinetics of TNF-a production by SIV-specific CD8+ T cells in blood shown in Figure 2A (blue) and CD8+ T cell-
mediated SIV-suppressive activity in blood shown in Figure 3A (orange) in SICs (left panel) and VIRs (right panel). Median and interquartile range are shown (n = 12
SICs; n = 4 VIRs).
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HIV-suppressive capacity ex vivo (Le´curoux et al., 2014). There-
fore, the development of efficient CD8+ T cell responses with
antiviral activity is a characteristic of most HICs/SICs, indepen-
dent of their MHC background.
Skewed Maturation of Central Memory SIV-Specific
CD8+ T Cells Is Associated with Defective Acquisition of
SIV-Suppressive Activity
To dissect the phenotypic correlates of antiviral potency
measured ex vivo, we analyzed the differentiation status of
SIV-specific CD8+ T cells using selected markers in conjunction
with MHC class I tetramers. Tetramer-binding SIV-specific
CD8+ T cells were detected in all CyMs and displayed early
similar differentiation profiles in SICs and VIRs but evolved
differently, such that higher frequencies of central memory
(CM) SIV-specific CD8+ T cells were present in SICs versus
VIRs on day 105 p.i. (p = 0.018) and day 535 p.i. (p = 0.013)
(Figures 5A and 5B).
In further analyses, we found that higher frequencies of SIV-
specific CD8+ T cells from SICs expressed the IL-7 receptor
CD127, which is associated with cell survival and memory re-
sponses (Schluns et al., 2000), whereas higher frequencies of
SIV-specific CD8+ T cells from VIRs expressed the transcription
factor T-bet, which is associated with cellular differentiation and
effector functionality (Sullivan et al., 2003; Szabo et al., 2002)
(Figure 6A). These differences seemed to appear since primary
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Figure 6. Altered Maturation of CM SIV-Specific CD8+ T Cells in VIRs
(A) Dynamics of T-bet expression (left panels) and CD127 expression (right panels) among SIV-specific CD8+ T cells in SICs (n = 12, gray) and VIRs (n = 4, red).
(B) Dynamics of T-bet expression (left) and CD127 expression (right) among CM, TM, EM, and Eff SIV-specific CD8+ T cells.
*p < 0.05, **p < 0.01; Mann-Whitney U test.
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Figure 7. Skewed Maturation of CM SIV-Specific CD8+ T Cells Is Associated with Defective Acquisition of SIV-Suppressive Activity
(A and B) Spearman correlations between CD127+ SIV-specific CD8+ T cell frequencies and VLs (A) or CD8+ T cell-mediated SIV-suppressive activity (B) during
acute infection (left panels) or chronic infection (right panels).
(legend continued on next page)
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infection, but because of the limited number of VIRs analyzed,
the differences only reached statistical significance at later
time points (Figure 6A). Expression levels of CD127 and T-
bet also varied as a function of differentiation amongSIV-specific
CD8+ T cells from SICs and VIRs (Figure 6B). In particular, CM
and transitional memory (TM) SIV-specific CD8+ T cells ex-
pressed lower levels of T-bet throughout the course of infection
in SICs versus VIRs, whereas CM SIV-specific CD8+ T cells
tended to express higher levels of CD127 during chronic infec-
tion in SICs versus VIRs.
To palliate the limited statistical power, we analyzed all ani-
mals together, taking into account the spectrum of outcomes
rather than group classifications. We found negative correlations
during primary infection and at euthanasia between the expres-
sion levels of CD127 on SIV-specific CD8+ T cells and plasma
VLs (Figure 7A). The levels of CD127 correlated positively with
CD8+ T cell-mediated SIV-suppressive activity at the same
time points (Figure 7B). In contrast, negative correlations were
observed during primary infection and at euthanasia between
CD8+ T cell-mediated SIV-suppressive activity and contempora-
neous frequencies of T-bet+CD127! SIV-specific CD8+ T cells
(Figure 7C) and between CD8+ T cell-mediated SIV-suppressive
activity and expression levels of T-bet among CM SIV-specific
CD8+ T cells (Figure 7D).
Altogether, these results point to the importance of the early
establishment and maintenance of optimal memory CD8+
T cell responses for achieving viral control. Recently, the pres-
ence of a population of memory-like CD8+ T cells with stem-
cell-like properties, characterized by the expression of the tran-
scription factor T cell factor 1 (TCF-1) (Zhou et al., 2010), was
shown to be critical to sustain the CD8+ T cell response against
chronic viral infections (Snell et al., 2018; Utzschneider et al.,
2016). We found that SIV-specific CMCD8+ T cells fromSICs ex-
pressed higher levels of TCF-1 than cells from VIRs (Figure 7E).
Among TCF-1-expressing cells, a higher frequency of cells
from SICs also expressed CXCR5 and CCR7, revealing the pres-
ence of memory-like responses with the potential capacity to
migrate to the LN follicles (Leong et al., 2016).
Collectively, these results suggest that SICs developed during
early-infection SIV-specific CD8+ T cells that enabled long-term
memory potential, sustained antiviral activity, and viral control,
whereas the corresponding SIV-specific CD8+ T cells in VIRs
adopt a skewed phenotype associated with cellular differentia-
tion and suboptimal antiviral activity and were more prone to
exhaustion (Zhou et al., 2010).
DISCUSSION
This study provides insights into the immune correlates of natural
SIV control. Although SIV-specific CD8+ T cells were generated
during acute infection with equivalent dynamics and global fre-
quencies in all CyMs, preventing discrimination between SICs
and VIRs, antiviral efficacy ex vivo developed progressively
over time and was associated with spontaneous SIV control.
This dichotomy was underpinned by distinct early-memory pro-
grams within the SIV-specific CD8+ T cell pool. Collectively,
these findings identify a cohesive set of immunological parame-
ters that associate with effective and sustained control of SIV.
To monitor the establishment of natural control prospectively,
we took advantage of previous reports showing that carriage of
the MHC haplotype M6 and i.r. inoculation with low-dose
(5AID50) virus independently favor spontaneous control of SIV-
mac251 infection in CyMs (Aarnink et al., 2011; Bruel et al.,
2015;Mee et al., 2009). Our results corroborate previous reports.
In particular, although the presence of the M6 haplotype favored
more frequent andmore rapid control of infection among animals
receiving a high dose of the virus (50AID50) (Table S4), no signif-
icant differences were observed in the dynamics of SIV control in
M6 and non-M6 SICs. At the time of euthanasia, a higher propor-
tion of CD4+ T cells and lower cell-associated SIV-DNA levels
were found in multiple tissues from SICs versus VIRs, demon-
strating systemic control of SIV. These differences were more
subtle during primary infection. However, PLNs from SICs
harbored approximately 10-fold less SIV-DNA in the acute phase
than PLNs from VIRs. In addition, the frequency of CD4+ T cells
was maintained close to baseline throughout the course of the
study in PLNs, but not in blood or RBs, from SICs. These obser-
vations suggest that early containment of viral replication in LNs
(Buggert et al., 2018; Reuter et al., 2017) may be a key event for
subsequent immune control of SIV.
In line with previous studies in humans (Le´curoux et al., 2013;
Ndhlovu et al., 2015; Trautmann et al., 2012) and non-human pri-
mates (Veazey et al., 2001), we observed early and robust ex-
pansions of SIV-specific CD8+ T cells in all CyMs. However,
the functional profiles and overall frequencies of SIV-specific
CD8+ T cells (as determined by intracellular cytokine staining
upon SIV antigen stimulation) during the acute phase of infection
were largely equivalent in SICs and VIRs, and neither parameter
correlated with subsequent determinations of plasma VL. Simi-
larly, the functional profiles and overall frequencies of SIV-spe-
cific CD8+ T cells during the chronic phase of infection were
largely equivalent in SICs and VIRs, although polyfunctionality
(defined as the capacity to simultaneously produce several cyto-
kines and/or degranulate) was impaired at the time of euthanasia
in VIRs. These results suggest that differences in polyfunctional-
ity found during chronic infection are a surrogate marker of viral
replication rather than an accurate determinant of antiviral effi-
cacy, although the low number of animals in the VIR group
may limit statistical power.
The capacity of CD8+ T cells to suppress infection of autolo-
gous CD4+ T cells directly ex vivo is a particular feature of
HICs (Almeida et al., 2009; Angin et al., 2016; Buckheit et al.,
(C and D) Spearman correlations between T-bet+ CD127! SIV-specific CD8+ T cell frequencies (C) or T-bet expression levels in CM SIV-specific CD8+ T cells (D)
and CD8+ T cell-mediated SIV-suppressive activity during acute infection (left panels) and chronic infection (right panels). Gray symbols, SICs (n = 12); red
symbols, VIRs (n = 4).
(E) Expression levels of TCF-1 among total, CM, TM, EM, and Eff SIV-specific CD8+ T cells (left panel) and proportion of SIV-specific CD8+ T cells coexpressing
TCF-1, CCR7, and CXCR5 (right panel). Median and interquartile range are shown.
**p < 0.01; Mann-Whitney U test.
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2012; Julg et al., 2010; Sa´ez-Cirio´n et al., 2007, 2009; Tansiri
et al., 2015) that is mediated by the rapid elimination of infected
CD4+ T cells through MHC-restricted mechanisms (Sa´ez-Cirio´n
et al., 2007). Irrespective of subsequent outcome, we detected
relatively weak CD8+ T cell-mediated SIV-suppressive activity
during primary infection, despite the vigorous mobilization of
SIV-specific CD8+ T cells. This observation parallels our previous
findings in the setting of HIV (Le´curoux et al., 2013) and points to
limited antiviral potential of CD8+ T cell responses generated
during primary infection. However, a negative correlation was
already observed between CD8+ T cell-mediated SIV-suppres-
sive activity and viremia at this early time point, showing early
temporal association of this antiviral activity and reduction of
viremia. This SIV-suppressive capacity of CD8+ T cells increased
progressively over a period of weeks in some animals, carrying
or not the protective MHC haplotype M6. At the time of eutha-
nasia, these highly potent antiviral CD8+ T cells were present in
all tissues in SICs, with the exception of bone marrow, where
this activity tended to be higher in SICs but overall weaker than
in other tissues. CD8+ T cell-mediated SIV suppression was
also weak in PLNs during the first weeks following infection but
increased over time in SICs. Therefore, the increase in the ca-
pacity of CD8+ T cells to suppress infection was not the result
of the recirculation of CD8+ T cells from LNs once control was es-
tablished but a genuine progressive augmentation of the antiviral
potential of the cells. The development of potent antiviral CD8+
T cells is therefore a bone fide correlate of sustained control of
SIV.
We provide several arguments supporting that the progressive
enhancement of the capacity of CD8+ T cells to suppress SIV
infection led to the establishment of controlled viremia, rather
than evolving as a consequence of viral control. Because the dy-
namics of control were not homogeneous, we established a
mathematical model to predict the development of effective im-
mune-mediated control of SIV in our study (Madelain et al.,
2020). Importantly, the model was constructed using SIV-RNA
and SIV-DNA data exclusively from VIRs and SICs. SIV-RNA ki-
netics were best fitted using a model in which the cytotoxic im-
mune response progressively mounted. The model predicted
that faster decay in VL in SICs was associated with progressive
development of a cytotoxic CD8+ T cell response that decreased
more than ten times the half-life of infected cells (from 5.5 days to
0.3 days). The model also predicted that in SICs, the maximal
level of cytotoxic responsewas reachedwithin 100 days of infec-
tion. The predictions of the kinetics of development of cytotoxic
CD8+ T cell responses matched, in post hoc analyses, the values
of the capacity of CD8+ T cells to suppress infection that we ob-
tained experimentally, but not the frequency of CD8+ T cells that
responded to SIV peptides. Moreover, we found that SIV-sup-
pressive activity of CD8+ T cells 70 days after infection correlated
negatively with ulterior VLs, although the suppressive activity
never correlated negatively with preceding VLs. Control of
viremia driven by antiretroviral treatment did not lead to the
development of SIV-suppressive activity by CD8+ T cells. There-
fore, the enhancement of SIV-suppressive capacity does not
occur in response to a decrease in antigen levels.
However, because of limited longitudinal sampling in lymphoid
tissues, we cannot exclude that SIV control or emergence of SIV-
suppressive capacity by CD8+ T cells in these tissues preceded
our observations. Moreover, the progressive establishment of
control of infection and maturation of the CD8+ T cell response
might be the result of a virtuous circle, in which initial reduced dy-
namics of viral replication in LNs allowed the development of
more effective CD8+ T cell responses, which in turn droved a
steeper reduction in viremia. ‘‘Goldilocks’’ levels of viral replica-
tion might then allow CD8+ T cells to attain their maximal antiviral
potential and sustain viral control, as has been proposed to
occur in cytomegalovirus (CMV) infection (Picker, 2014).
CD8+ T cells that can control certain latent chronic viral infec-
tions, such as CMV or Epstein-Barr virus (EBV), do not show fea-
tures of functional exhaustion when compared with CD8+ T cells
against other chronic viral infections, such as SIV/HIV, hepatitis
C virus (HCV), or hepatitis B virus (HBV) (Chatterjee et al.,
2019; Fenwick et al., 2019; Luxenburger et al., 2018; van den
Berg et al., 2019; Ye et al., 2015). This appears to be related to
the development of CD8+ T cells with distinct molecular pro-
grams that allow long-term memory and replenishment of the
effector compartment in response to antigenic stimulation (Paley
et al., 2012). Recent studies have identified a subset of memory-
like CD8+ T cells that express the transcription factor TCF-1 as
responsible for sustaining the immune response against chronic
viral infections (Utzschneider et al., 2016). CD8+ T cells express-
ing TCF-1 have characteristics of CM cells, possess strong pro-
liferative potential, and are able to produce a more differentiated
cell subset while being less prone to exhaustion after repeated
antigenic stimulation (Snell et al., 2018; Utzschneider et al.,
2016; Zhou et al., 2010). We found that SIV-specific CD8+
T cells from SICs expressed higher levels of TCF-1 than cells
from VIRs, and these differences were more visible among less
differentiated subsets and coupledwith an enhanced expression
of CXCR5, which may reflect the potential of these cells to
migrate to germinal centers. During the revision of this manu-
script, a preprint became available describing similar findings
in cells from both HICs and SICs in an independent study (Ru-
tishauser et al., 2020). In that study, the authors linked the
expression of TCF-1 with the capacity of HIV-specific CD8+
T cells to expand.
One decisive characteristic for the establishment of long-term
memory is the capacity to upregulate the IL-7 receptor a subunit
(CD127) (Huster et al., 2004). In addition, studies in mice have
shown that decreased expression of T-bet among memory
CD8+ T cells allows the establishment of long-lived CD127hi
cells, which maintain the capacity to proliferate and control suc-
cessive infections (Joshi et al., 2007, 2011). In our study, the
divergent outcome of SICs versus VIRs was preceded by early
differences in the expression of CD127 and T-bet, especially
within the less differentiated memory pool (CM and TM). In
particular, at day 21 p.i., higher frequencies of SIV-specific CM
CD8+ T cells expressed CD127 in SICs, whereas higher fre-
quencies of SIV-specific CM and TM CD8+ T cells expressed
T-bet in VIRs. Plasma viremia was uncontrolled at this time point
and largely equivalent in animals that became SICs (median 5.19
log SIV-RNA) or VIRs (median 5.36, p = 0.65). The phenotypic dif-
ferences remained consistent or even appeared to becomemore
pronounced throughout the course of infection, although the sta-
tistical power of the analyses was affected by the limited number
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of VIRs studied. Overall, our data suggest that SICs develop
early-memory-like SIV-specific CD8+ T cell responses, whereas
VIRs develop SIV-specific memory CD8+ T cell responses
skewed toward more effector-like characteristics; they also sug-
gest that these differences may be determinant to achieving and
sustaining viral control. These findings are broadly consistent
with several previous reports describing immune profiles that
associate with the control of viremia in HICs during chronic infec-
tion. Favorable characteristics include high frequencies of
CD57+ eomesoderminhi HIV-specific CD8+ T cells with superior
proliferative capacity, increased expression levels of CD127,
and intermediate expression levels of T-bet (Simonetta et al.,
2014), as well as high frequencies of HIV-specific CD8+ T cells
with the capacity to upregulate T-bet, granzyme B, and perforin
in response to antigen encounter (Hersperger et al., 2011b; Mi-
gueles et al., 2008).
In a single-cell study (Angin et al., 2019), we also found differ-
ences in the program of HIV-specific CM CD8+ T cells from HICs
and non-controllers. Although HIV-specific CM CD8+ T cells
from HICs upregulated the expression of effector genes linked
with mTORC2 activation and cell survival (including CD127),
CM cells from non-controllers had a skewed profile associated
with mTORC1 activation (including T-bet) and glycolysis. This
was traduced in a dependency on glucose of HIV-specific
CD8+ T cells from non-controllers to react to HIV antigens,
whereas HIV-specific CD8+ T cells fromHICswere characterized
by metabolic plasticity and were able to exert their function even
in conditions of glucose deprivation. These differences in the
metabolic program of cells from controllers and non-controllers
could be recapitulated with SIV-specific CD8+ T cells from SICs
and VIR macaques from the present study (Angin et al., 2019),
corroborating the validity of our CyM model to study the devel-
opment of the protective CD8+ T cell response characteristics
of HICs and SICs. The present results extend these observations
and support a key role for long-lived memory responses in the
control of SIV. Importantly, our data also show that distinct mem-
ory responses are formed early after infection, potentially reflect-
ing different priming conditions.
Several important questions remain unresolved. It remains
unclear which factors are required to encourage the develop-
ment of memory CD8+ T cell responses that provide optimal
protection against HIV/SIV. In some viral infections, expression
of T-bet is tightly regulated by cytokines, such as IL-12 (Rao
et al., 2012; Takemoto et al., 2006). A recent study in the lym-
phocytic choriomeningitis virus (LCMV) murine model of infec-
tion suggests that memory-like TCF-1 CD8+ T cell responses
with stemness potential and enhanced capacity to react upon
secondary challenge are developed during early chronic infec-
tion (in an immunosuppressive environment), whereas memory
cells that are developed at the onset of infection (in a pro-in-
flammatory environment) become short-term effectors and
are rapidly exhausted (Snell et al., 2018). Based on these ob-
servations, we propose that balanced inflammatory responses
(Barouch et al., 2016) arising as a consequence of lower viral
burdens in the LNs during acute infection in SICs might facili-
tate antigen-specific priming events associated with optimal
memory programs (Ozga et al., 2016) and minimize the loss
of CD4+ T cells, which provide helper functions that are critical
for the development of long-lived memory-like CD8+ T cells
(Khanolkar et al., 2004; Utzschneider et al., 2016). However, it
is unclear which mechanisms were responsible for the reduced
viral dynamics in the LNs of SICs during acute infection. In the
case of animals carrying the M6 haplotype, this could be
related to more effective natural killer (NK) cell responses, as
has been shown for humans carrying some protective HLA al-
leles (Martin et al., 2002). For animals inoculated with a lower
dose of the virus, this could result from less diversity of infect-
ing viruses (Liu et al., 2010), which could limit the inflammatory
response and be more efficiently controlled by initial CD8+
T cell responses. Although we have shown that the changes
in the suppressive capacity of CD8+ T cells were related to
intrinsic functional properties of the cells, not to different ca-
pacities to react against evolving viruses, a better understand-
ing of the evolution of viral diversity and the quality of immune
responses appears important in light of our results. Finally, we
found that the proportion of CD127+ SIV-specific CD8+ T cells
during acute and chronic infection correlated positively with
CD8+ T cell-mediated SIV-suppressive activity, and we pro-
pose that the amplification of potent antiviral activity is the
result of a maturation process, the trajectory of which is linked
to the early optimal programming of the CD8+ T cell memory
compartment. However, we do not have direct evidence at
the molecular level to explain why or how the capacity to sup-
press infection increased progressively among CD8+ T cells.
Maturation through persistent or repeated exposure to antigen
can drive the selection of specific clonotypes bearing high-af-
finity T cell receptors (TCRs) (Busch and Pamer, 1999; Ozga
et al., 2016; Price et al., 2005), which have been shown to sup-
press HIV replication more efficiently than clonotypes targeting
the same antigen via low-affinity TCRs (Almeida et al., 2007,
2009; Ladell et al., 2013; Lima et al., 2020). Increase in antigen
sensitivity over time would be compatible with the progressive
increase in antiviral potency that we observed for the CD8+
T cells from controllers in our study.
Collectively, the data presented here underscore the impor-
tance of early host-pathogen interactions in the development
of adaptive immunity and reveal an optimal maturation pathway
associated with the generation and maintenance of potent and
sustained antiviral CD8+ T cell responses, which in turn dictate
the outcome of infection with SIV.
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Lead Contact
Further information and requests for resources and reagents should be directed to the Lead Contact, Asier Saez-Cirion (asier.
saez-cirion@pasteur.fr). Request for biological resources will be fulfilled based on availability and upon the establishment of a MTA.
Materials Availability
This study did not generate new unique reagents.
Data and Code Availability
This study did not generate/analyze datasets/code.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Ethical statement
CyMs were imported from Mauritius and housed in facilities at the Commissariat a` l’Energie Atomique et aux Energies Alternatives
(CEA, Fontenay-aux-Roses, France). All non-human primate studies at the CEA are conducted in accordance with French National
Regulations under the supervision of National Veterinary Inspectors (CEA Permit Number A 92-03-02). The CEA complies with the
Standards for Human Care and Use of Laboratory Animals of the Office for Laboratory Animal Welfare under Assurance Number
#A5826-01. All experimental procedures were conducted according to European Directive 2010/63 (Recommendation Number 9).
The SIC and pVISCONTI studies were approved and accredited under statements A13-005 and A15-035 from the ‘‘Comite´ d’Ethique
en Expe´rimentation Animale du CEA’’, registered and authorized under Number 44 and Number 2453-2015102713323361v2 by the
French Ministry of Education and Research. CyMs were studied with veterinary guidance, housed in adjoining individual cages al-
lowing social interactions, and maintained under controlled conditions with respect to humidity, temperature, and light (12 hr
light/12 hr dark cycles). Water was available ad libitum. Animals were monitored and fed with commercial monkey chow and fruit
once or twice daily by trained personnel. Environmental enrichment was provided in the form of toys, novel foodstuffs, and music
under the supervision of the CEA Animal Welfare Body. Experimental procedures (animal handling, viral inoculations, and samplings)
were conducted after sedation with ketamine chlorhydrate (Imalgene 1000!, 10 mg/kg, i.v., Merial). Tissues were collected at nec-
ropsy. Animals were sedated with ketamine chlorhydrate and euthanized humanely with sodium pentobarbital (Dole´thal, 180 mg/kg,
i.v., Laboratoire Vetoquinol).
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CCTGCCATTAAGCCCGA-BHQ1-30
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CCR5 F: 50-CAACATGCTG
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ATACTGGTCGTCCTCATCC-30
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CCR5 R: 50-CAGCATAGT
GAGCCCAGAAG-30
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GraphPad version 8.1.2 Graphpad https://www.graphpad.com
SigmaPlot version 12.5 SYSTAT Software http://www.sigmaplot.co.uk/products/
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Animals and SIV infection
A total of 16 healthy adult male CyMs (median age = 6.8 years at inclusion, IQR = 5.8–7.2) were selected for this study on the basis of
MHC haplotype (M6+, n = 6; M6!, n = 10) (Aarnink et al., 2011). CyMs were inoculated i.r. with either 5AID50 or 50AID50 of uncloned
SIVmac251 (A.M. Aubertin, Universite´ Louis Pasteur, Strasbourg, France). The following experimental groups were studied: (i) M6!
CyMs inoculated i.r. with 5AID50 (non-M6 5AID50, n = 4); (ii) M6
+ CyMs inoculated i.r. with 50AID50 (M6 50AID50, n = 6); and (iii) M6
!
CyMs inoculated i.r. with 50AID50 (non-M6 50AID50, n = 6). Animals were monitored for 18 months after infection.
The outcome of infection generally matched expectations based on previous studies for each experimental group (Figure S7A; Ta-
ble S4). Only oneM6+ CyM (31041) was unable to control viremia below 400 copies/mL. This animal was homozygous forMHC class I
(Table S1), which intrinsically limits immune control of HIV/SIV (Carrington et al., 1999; O’Connor et al., 2010). The dynamics of viral
replication during acute infection were very similar in the three experimental groups, with peak VLs of 5.9, 6.4, and 6.3 log SIV-RNA
copies/mL of plasma on day 14 p.i. for non-M6 5AID50, M6 50AID50, and non-M6 50AID50 CyMs, respectively (Table S4).
CyMs in the pVISCONTI study (median age = 5 years at inclusion, IQR = 4.1–5.3) were inoculated i.v. with 1000 AID50 of uncloned
SIVmac251. None of these animals carried the M6 haplotype. An antiretroviral regimen containing emtricitabine (FTC, 40 mg/kg, Gi-
lead), dolutegravir (DTG, 2.5 mg/kg, ViiV Healthcare), and the tenofovir prodrug tenofovir-disoproxil-fumarate (TDF, 5.1 mg/kg, Gi-
lead), coformulated as a once daily subcutaneous injection, was initiated on day 28 p.i. in 6 animals.
METHOD DETAILS
Blood collection and processing
Peripheral blood was collected by venous puncture into Vacutainer Plus Plastic K3EDTA Tubes or Vacutainer CPT Mononuclear Cell
Preparation Tubes with Sodium Heparin (BD Biosciences). Complete blood counts were monitored at all time points from the Vacu-
tainer Plus Plastic K3EDTA Tubes. Plasma was isolated from Vacutainer Plus Plastic K3EDTA Tubes by centrifugation for 10 min at
1,500 g and stored at !80"C. Peripheral blood mononuclear cells (PBMCs) were isolated from Vacutainer CPT Mononuclear Cell
Preparation Tubes with Sodium Heparin according to manufacturer’s instructions (BD Biosciences), and red blood cells were lysed
in ACK (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.4).
Tissue collection and processing
Axillary or inguinal LNs (PLNs), RBs, and broncho-alveolar lavages (BALs) were collected longitudinally from each animal at the indi-
cated time points. Bone marrow, spleen, mesenteric lymph nodes (MLNs), duodenum, jejunum, ileum, and colon were collected at
necropsy. Tissue samples were snap-frozen in liquid nitrogen for storage at !80"C or collected in RPMI medium at 2–8"C. A
complete PLN group was collected at each time point. LN cells were isolated into RPMI medium via mechanical disruption using
a gentleMACS Dissociator (Miltenyi Biotec). The cell suspension was filtered (70 mm), and red blood cells were lysed in ACK. RB lym-
phocytes were obtained from approximately 4 mm2 of rectal mucosa. Colonic lymphocytes were obtained from mucosa taken from
approximately 10 cm of tissue. RBs and colonic tissue were washed extensively in R10 medium (RPMI medium supplemented with
10% fetal calf serum and penicillin/neomycin/streptomycin), and then digested for 45 min with collagenase II prior to mechanical
disruption. Lymphocytes were isolated over a Percoll 67/44 gradient (Sigma-Aldrich). Bone marrow cells were purified using
Lymphocyte Separation Medium (Lonza Bioscience) diluted to 90% in DPBS, centrifuged for 20 min at 350 g, and separated from
red cells in ACK. Spleen cells were processed via mechanical disruption in RPMI medium using a gentleMACS Dissociator (Miltenyi
Biotec), purified as described for bone marrow cells, and separated from red cells in ACK. T-cell activation and proliferation assays
and measurements of SIV-suppressive activity were performed using freshly isolated cells, and intracellular cytokine assays and
tetramer stains were performed using cells frozen viably at !80"C.
Quantification of plasma viral load
Plasma viremia wasmonitored longitudinally in all animals using quantitative RT-PCRwith a limit of detection of 12.3 copies/mL. Viral
RNA was prepared from 100 mL of cell-free plasma. Quantitative RT-PCR was performed using a SuperScript III Platinum One-Step
qRT-PCR Kit (Thermo Fisher Scientific) with a CFX96 Touch Real-Time PCR Detection System (Bio-Rad). Each tube contained
12.5 mL of 2X reaction mixture, 0.5 mL of RNaseOUT (40 U/mL), 0.5 mL of Superscript III Reverse Transcriptase/Platinum Taq DNA
Polymerase, 1 mL of each primer (125 mM), 0.5 mL of the fluorogenic probe (135 mM), and 10 mL of eluted RNA. Primer/probe
sequences were designed to amplify a region of SIVmac251 gag. The forward (F) primer sequence was 50-GCAGAGGAGGAAAT
TACCCAGTAC-30 (24 bp), and the reverse (R) primer sequence was 50-CAATTTTACCCAGGCATTTAATGTT-30 (25 bp). The probe
sequence was 50-FAM-TGTCCACCTGCCATTAAGCCCGA-BHQ1-30 (23 bp). This probe had a fluorescent reporter dye, FAM (6-car-
boxyfluorescein), attached to its 50 end and a quencher, BHQ1 (Black Hole Quencher 1), attached to its 30 end (TaqMan, Applied Bio-
systems). Samples were heated for 30min at 56"Cand 5min at 95"C, followed by 50 thermocycles, each comprising 15 s at 95"Cand
1 min at 60"C.
Quantification of SIV-DNA
Total DNA was extracted from purified CD14+ alveolar macrophages, buffy coats, and snap-frozen tissues. CD14+ alveolar macro-
phages were purified magnetically via positive selection using CD14 MicroBeads (Miltenyi Biotec). Purity was checked using flow
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cytometry (Figure S1B). Snap-frozen tissues were mechanically disrupted using a MagNA Lyser (Roche Diagnostics). DNA was ex-
tracted using aQIAampDNABloodMini Kit (QIAGEN). SIV-DNAwas quantified using an ultrasensitive quantitative real-time PCR. For
blood samples, 150,000 cells were analyzed in each PCR. Sample limitations restricted input numbers to 20,000 cells for BALs and
50,000 cells for RBs. All amplifications were performed over 2–4 replicates. The cell line SIV1C, which contains 1 copy of SIV
integrated/cell, was used as a standard for quantification. A total of 1 mg of DNA was considered to be equivalent to 150,000 cells.
Amplification was performed using primers and a probe located in the gag region. The CCR5 gene was used to normalize results per
million cells. Results were adjusted by the frequencies of CD4+ T cells in blood and tissues, according to availability. The limit of
quantification was 2 copies/PCR. Primer and probe sequences were: SIV gag F: 50-GCAGAGGAGGAAATTACCCAGTAC-30; SIV
gag R: 50-CAATTTTACCCAGGCATTTAATGTT-30; SIV gag probe: 50-FAM-TGTCCACCTGCCATTAAGCCCGA-BHQ1-30; CCR5 F:
an equimolar mix of 50-CAACATGCTGGTCGATCCTCAT-30 and 50-CAACATACTGGTCGTCCTCATCC-30; CCR5 R: 50-CAGCATAGT
GAGCCCAGAAG-30; and CCR5 probe: 50-HEX-CTGACATCTACCTGCTCAACCTG-BHQ1-30.
Viral reactivation in autologous CD4+ T cells
Autologous CD4+ T cells were purifiedmagnetically from freshly isolated PBMCs using an EasySepCD4 Positive Selection Kit with an
automated RoboSep (StemCell Technologies). Purified CD4+ T cells were stimulated for 3 dayswith concanavalin A (5 mg/mL, Sigma-
Aldrich) in the presence of IL-2 (100 IU/mL,Miltenyi Biotec). Stimulated CD4+ T cells (105) were cultured in R10medium containing IL-
2 (100 IU/mL, Miltenyi Biotec). The production of SIV p27 was measured in culture supernatants on day 7 using an SIV p27 Antigen
ELISA Kit (Zeptometrix).
Measurement of T cell activation and proliferation
T cell activation and proliferation were assessed using fresh PBMCs and tissue cell suspensions. Blood samples were treated with
FACS Lysing Solution (BD Biosciences). Cells were surface stained for CD3, CD4, CD8, CD38, CD45, CCR5, and HLA-DR, fixed/per-
meabilized using a Cytofix/CytoPerm Kit (BD Biosciences), and stained intracellularly for Ki-67. The following antibodies used were:
anti-CD3–PE (clone SP34-2, BD Biosciences), anti-CD4–PerCP-Cy5.5 (clone L200, BD Biosciences), anti-CD8–BV650 (clone RPA-
T8, BioLegend), anti-CD38–FITC (clone AT-1, StemCell Technologies), anti-CD45–V500 (clone D058-1283, BD Biosciences), anti-
CCR5–APC (clone 3A9, BD Biosciences), anti-HLA-DR–APC-H7 (clone G46-6, BD Biosciences), and anti-Ki-67–AF700 (clone
B56, BD Biosciences). Data were acquired using an LSRII flow cytometer (BD Biosciences) and analyzed with FlowJo software
version 10 (Tree Star Inc.).
Intracellular cytokine staining
Frozen PBMCs, PLN cells, bonemarrow cells, splenocytes, andMLN cells were thawed, resuspended at 13 106/mL in R20medium,
and stored overnight at 37"C. Cells were then stimulated with a pool of 24 optimal SIV peptides (8–10 amino acids, 2 mg/mL each;
Table S3) or with a pool of 125 overlapping SIV Gag 15-mer peptides (SIVmac239 Gag Peptide Set #12364, 2 mg/mL each, NIH AIDS
Reagent Program) in the presence of anti-CD28 (1 mg/mL, clone L293, BD Biosciences) and anti-CD49d (1 mg/mL, clone 9F10, BD
Biosciences) and stained with anti-CD107a (clone H4A3, BD Biosciences) for 30 min prior to the addition of GolgiStop (1 mL/mL, BD
Biosciences) and brefeldin A (BFA, 5 mg/mL, Sigma-Aldrich). Costimulatory antibodies alone were used as a negative control, and
concanavalin A (5 mg/mL, Sigma-Aldrich) was used as a positive control. Cells were incubated for a total of 6 hr. After washing, cells
were surface stained for CD3, CD4, and CD8, fixed/permeabilized using a Cytofix/CytoPerm Kit (BD Biosciences), and stained intra-
cellularly for IFNg, TNFa, and IL-2. The following antibodies were used: anti-CD107a–V450 (clone H4A3, BD Biosciences), anti-CD3–
AF700 (clone SP34-2, BD Biosciences), anti-CD4–PerCP-Cy5.5 (clone L200, BD Biosciences), anti-CD8–APC-Cy7 (clone RPA-T8,
BDBiosciences), anti-IFNg–PE-Cy7 (clone B27, BDBiosciences), anti-IL-2–PE (cloneMQ1-17H12, BDBiosciences), and anti-TNFa–
PE-CF594 (clone Mab11, BD Biosciences). Data were acquired using an LSRII flow cytometer (BD Biosciences) and analyzed with
FlowJo software version 10 (Tree Star Inc.). Results were corrected for background by subtracting the negative (no peptide) control
from the peptide stimulated response. Negative responses were given an arbitrary value of 0.001.
MHC class I tetramer staining
Biotinylated complexes of Nef RM9 (RPKVPLRTM)–Mafa A1*063:02, Gag GW9 (GPRKPIKCW)–Mafa A1*063:02, and Vpx GR9 (GEA-
FEWLNR)–Mafa B*095:01 were produced as described previously (Price et al., 2005). The corresponding tetramers were generated
via the stepwise addition of APC-conjugated streptavidin (Thermo Fisher Scientific). Frozen PBMCs were stained with all tetramers
simultaneously for 30 min at 37"C, washed, and surface stained for CD3, CD4, CD8, CD14, CD20, CD27, CD45RA, CCR7, HLA-DR,
and CD127. Cells were then fixed/permeabilized using a Cytofix/CytoPerm Kit (BD Biosciences) and stained for T-bet. The following
antibodies were used: anti-CD3–AF700 (clone SP34-2, BD Biosciences), anti-CD4–PerCP-Cy5.5 (clone L200, BD Biosciences), anti-
CD8–APC-Cy7 (clone RPA-T8, BDBiosciences), anti-CD14–BV786 (cloneM5E2, BDBiosciences), anti-CD20–BV786 (clone L27, BD
Biosciences), anti-CD27–PE (clone M-T271, BD Biosciences), anti-CD45RA–PE-Cy7 (clone 5H9, BD Biosciences), anti-CCR7–PE-
Dazzle594 (clone G043H7, BioLegend), anti-HLA-DR–Pacific Blue (clone G46-6, BD Biosciences), anti-CD127–FITC (clone MB15-
18C9, Miltenyi Biotec), and anti-T-bet–BV711 (clone 4B10, BioLegend). Data were acquired using an AriaIII flow cytometer (BD Bio-
sciences) and analyzed with FlowJo software version 10 (Tree Star Inc.). MFI stands for median fluorescence intensity.
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TCF-1 staining
Frozen splenocytes were stained with tetramers as described above, washed, and surface stained for CD3, CD4, CD8, CD14, CD20,
CD27, CD45RA, CCR7, and CXCR5. Cells were then fixed/permeabilized using a Transcription Factor Buffer Set (BD Biosciences)
and stained for TCF-1. The following antibodies were used: anti-CD3–AF700 (clone SP34-2, BD Biosciences), anti-CD4–PerCP-
Cy5.5 (clone L200, BD Biosciences), anti-CD8–APC-Cy7 (clone RPA-T8, BD Biosciences), anti-CD14–BV786 (clone M5E2, BD
Biosciences), anti-CD20–BV786 (clone L27, BD Biosciences), anti-CD27–BUV395 (clone M-T271, BD Biosciences), anti-
CD45RA–PE-Cy7 (clone 5H9, BD Biosciences), anti-CCR7–PE-Dazzle594 (clone G043H7, BioLegend), anti-CXCR5–BV710 (clone
RF8B2, BD Biosciences), and anti-TCF-1–PE (clone S33-966, BD Biosciences). Data were acquired using an AriaIII flow cytometer
(BD Biosciences) and analyzed with FlowJo software version 10 (Tree Star Inc.).
Measurement of SIV-suppressive activity
Autologous CD4+ and CD8+ T cells were purified from freshly isolated PBMCs or tissue cell suspensions by positive and negative
selection, respectively, using the relevant EasySep Kits with an automated RoboSep (StemCell Technologies). Purified CD4+
T cells were stimulated for 3 days with concanavalin A (5 mg/mL, Sigma-Aldrich) in the presence of IL-2 (100 IU/mL, Miltenyi Biotec).
Purified CD8+ T cells were cultured in the absence of mitogens and cytokines (ex vivo CD8+ T cells). Stimulated CD4+ T cells (105)
were superinfected in U-bottom 96-well plates with SIVmac251 (MOI = 10!3) in the presence (1:1 effector-to-target-cell ratio) or
absence of ex vivo CD8+ T cells (105) from the same tissue via spinoculation for 1 hr (1,200 g at room temperature) and incubated
for 1 hr at 37"C. Purified CD4+ and CD8+ T cells were separated in some assays using HTS Transwell-96 Permeable Supports
with 0.4-mm Pore Polycarbonate Membranes (Corning). Cells were then washed and cultured in R10 medium containing IL-2 (100
IU/mL, Miltenyi Biotec). Culture supernatants were assayed on day 7 using an SIV p27 Antigen ELISA Kit (Zeptometrix). Suppression
of autologous virus was assessed similarly without superinfection. Antiviral activity was calculated as log10 (mean p27 ng/mL in SIV-
infected CD4+ T cell cultures without ex vivo CD8+ T cells) / (mean p27 ng/mL in SIV-infected CD4+ T cell cultures with ex vivo CD8+
T cells) (Sa´ez-Cirio´n et al., 2010).
QUANTIFICATION AND STATISTICAL ANALYSIS
Data visualization was performed using Tableau version 2018.1.4 (Tableau Software). Statistical analyses were performed using
Prism version 8.1.2 (GraphPad Software) and SigmaPlot version 12.5 (SYSTAT Software). Results are presented as median ±
IQR. Groups were compared using theMann-Whitney U-test. Correlations were assessed using Spearman rank analyses. No adjust-
ments were made for multiple comparisons, given the exploratory nature of the analyses. All p values less than 0.05 were defined as
significant.
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